AmoyDx® MET Mutation Detection Kit | 8.01.26101X024H

AmoyDx® MET Mutation Detection Kit | 8.01.26101X024H | Gentaur UK, US & Europe Distribution  

Lung cancer is one of the most common malignant tumor, and 80〜85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC, and MET alterations that result in exon 14 skipping are also found. MET exon 14 skipping mutations have been identified in approximately 3~4% of lung adenocarcinoma patients. Studies have shown that NSCLC patients harboring MET mutations causing exon 14 skipping response to MET-targeted therapy, as the presence of exon 14 skipping mutation in the MET gene is associated with increased sensitivity of MET inhibitors.

Intended Use

The AmoyDx® MET Mutation Detection Kit is a real-time PCR assay for qualitative detection of exon 14 skipping mutation in MET gene in human total RNA extracted from NSCLC formalin-fixed paraffin-embedded (FFPE) tissue samples.

Testing Procedure